Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TherapeuticsMD Inc    TXMD

THERAPEUTICSMD INC (TXMD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
5.48(c) 5.38(c) 5.47(c) 5.52(c) 5.58(c) Last
1 601 683 1 010 991 1 426 105 1 342 114 1 409 518 Volume
+1.29% -1.82% +1.67% +0.91% +1.09% Change
More quotes
Financials ($)
Sales 2017 17,6 M
EBIT 2017 -75,2 M
Net income 2017 -74,9 M
Finance 2017 137 M
Yield 2017 -
Sales 2018 29,8 M
EBIT 2018 -98,1 M
Net income 2018 -92,4 M
Finance 2018 35,5 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 60,1x
EV / Sales2018 38,9x
Capitalization 1 195 M
More Financials
Company
TherapeuticsMD, Inc. is a healthcare company, which focuses on developing and commercializing products for women.Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration... 
Sector
Pharmaceuticals
Calendar
02/20Earnings Release
More about the company
Surperformance© ratings of TherapeuticsMD Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on THERAPEUTICSMD INC
02/06THERAPEUTICSMD : to Host Fourth Quarter and Year End 2017 Financial Results Conf..
BU
01/09THERAPEUTICSMD, INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
01/05THERAPEUTICSMD : International Academy of Compounding Pharmacists Announcement
AQ
01/03THERAPEUTICSMD : Announces Presentation at 36th Annual J.P. Morgan Healthcare Co..
BU
2017THERAPEUTICSMD : Submits NDA to FDA, Shares Jump
AQ
2017THERAPEUTICSMD : Announces Submission of New Drug Application for TX-001HR
BU
2017THERAPEUTICSMD : Announces FDA Acceptance of New Drug Application and Prescripti..
AQ
2017THERAPEUTICSMD, INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
2017THERAPEUTICSMD : Announces FDA Acceptance of New Drug Application and Prescripti..
BU
2017THERAPEUTICSMD : Announces Resubmission of New Drug Application for TX-004HR
BU
More news
Sector news : Specialty & Advanced Pharmaceuticals
03:15pNOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
02/16Upcoming #earnings reports
1
02/15$TXMD - Jefferies Group Weighs in on TherapeuticsMD Inc's FY2020 Earnings #TX.. 
02/15Jefferies Group Weighs in on TherapeuticsMD Inc’s FY2020 Earnings $TXMD  
02/15Jefferies Group Lowers TherapeuticsMD FY2018 Earnings Estimates to ($0.45) EP.. 
02/15Research Report Identifies Louisiana-Pacific, Vmware, ZAGG, FS Investment, Th.. 
More tweets
Qtime:21
News from SeekingAlpha
01/29Oppenheimer bullish on TherapeuticsMD, sees 57% upside 
2017YOUR DAILY PHARMA SCOOP : Progenics Azerda Update, Atara Gets FDA Clearance For .. 
2017YOUR DAILY PHARMA SCOOP : Intercept Updates On NASH Trial, GW Pharmaceuticals Pr.. 
2017After Hours Gainers / Losers 
2017TherapeuticsMD submits NDA for TX-001HR 
Chart THERAPEUTICSMD INC
Duration : Period :
TherapeuticsMD Inc Technical Analysis Chart | TXMD | US88338N1072 | 4-Traders
Technical analysis trends THERAPEUTICSMD INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 13,7 $
Spread / Average Target 149%
EPS Revisions
Managers
NameTitle
Robert G. Finizio Chief Executive Officer & Director
John C. K. Milligan President & Director
Tommy George Thompson Chairman
Daniel Alan Cartwright Chief Financial Officer, Treasurer & VP
Brian A. Bernick Director & Chief Clinical Officer
Sector and Competitors
1st jan.Capitalization (M$)
THERAPEUTICSMD INC-9.44%1 184
ABBVIE16.93%180 524
MERCK KGAA-8.06%13 375
KYOWA HAKKO KIRIN CO LTD4.50%12 695
JAZZ PHARMACEUTICALS PLC8.31%8 743
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.51%6 883